317
Participants
Start Date
August 17, 2023
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
Tenofovir Disoproxil Fumarate 300 MG
Pregnant women in the experimental arm will receive TDF daily beginning in the 3rd trimester of pregnancy and continuing through 1 month postpartum.
Hepatitis B monovalent vaccine
All infants born to women in the study will receive a birth-dose hepatitis B vaccine.
Placebo
Pregnant women in the placebo arm will receive a placebo pill daily beginning in the 3rd trimester of pregnancy and continuing through 1 month postpartum.
Université Protestant au Congo, Kinshasa
Collaborators (1)
Doris Duke Charitable Foundation
OTHER
Université Protestant au Congo
UNKNOWN
Abbott
INDUSTRY
Albert Einstein College of Medicine
OTHER
University of North Carolina, Chapel Hill
OTHER